ArticleAnnals of family medicine2025
Artificial Intelligence Tools for Preconception Cardiomyopathy Screening Among Women of Reproductive Age.
Article in Annals of family medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Artificial intelligence in preventive care in primary health care settings: a scoping review.Archives of medical sciences. Atherosclerotic diseases · 2026Article
- Information Technology in Primary Care Screenings: Ready for Prime Time?Annals of family medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
purposeIdentifying cardiovascular disease before conception and in early pregnancy can better inform obstetric cardiovascular care. Our main objective was to evaluate the diagnostic performance of artificial intelligence (AI)-enabled digital tools for detecting left ventricular systolic dysfunction (LVSD) among women of reproductive age.
methodsIn a pilot cross-sectional study, we enrolled an initial cohort of 100 consecutive women aged 18-49 years who had a primary care physician and a scheduled echocardiography at Mayo Clinic Florida (Jacksonville) (cohort 1). Twelve-lead electrocardiography (ECG) and digital stethoscope recordings (single-lead ECG + phonocardiography) were performed on the date of echocardiography. We used deep learning to generate prediction probabilities for LVSD (defined as left ventricular ejection fraction <50%) for the 12-lead ECG (AI-ECG) and stethoscope (AI-stethoscope) recordings. In a second cohort of 100 participants, we enrolled consecutive women seen in primary care to estimate the prevalence of positive AI screening results when deployed for routine use (cohort 2).
resultsThe median age of participants was 38.6 years (quartile 1: 30.3 years, quartile 3: 45.5 years), and 71.9% identified as part of the non-Hispanic White population. Among cohort 1, 5% had LVSD. The AI-ECG had an area under the curve of 0.94, and the AI-stethoscope (maximum prediction across all chest locations) had an area under the curve of 0.98. Among cohort 2, the prevalence of a positive AI screen was 1% and 3.2% for AI-ECG and the AI-stethoscope, respectively.
conclusionWe found these AI tools to be effective for the detection of cardiomyopathy associated with LVSD among women of reproductive age. These tools could potentially be useful for preconception cardiovascular evaluations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.